- Home
- EFSC vs STOK Comparison
EFSC vs STOK Comparison
Compare EFSC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EFSC | STOK |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EFSC | STOK |
|---|---|---|
| Price | $54.08 | $30.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $65.67 | $33.11 |
| AVG Volume (30 Days) | 202.6K | ★ 858.1K |
| Earning Date | 01-26-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 8.68 | N/A |
| EPS | ★ 5.13 | 0.68 |
| Revenue | ★ $646,694,000.00 | $205,632,000.00 |
| Revenue This Year | $20.14 | $430.24 |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | ★ $10.54 | $45.13 |
| Revenue Growth | 9.31 | ★ 1128.17 |
| 52 Week Low | $45.22 | $5.35 |
| 52 Week High | $62.60 | $38.69 |
Technical Indicators
Market Signals| Indicator | EFSC | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 47.77 |
| Support Level | $55.24 | $31.00 |
| Resistance Level | $55.66 | $32.50 |
| Average True Range (ATR) | 0.94 | 1.60 |
| MACD | -0.31 | -0.32 |
| Stochastic Oscillator | 18.16 | 9.24 |
Price Performance
Historical ComparisonAbout EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.